Research and development daily Roche multiple sclerosis drug Ocrevus has been approved by the FDA...

2020.12.15 Research and development NEWS: Roche multiple sclerosis drug Ocrevus was approved by the FDA again; platinum pharmaceutical jointly announced the approval of AbbVie's new coronary antibody Phase 1 clinical trial started; Novartis JAK inhibitor Jakavi treatment hospitalized COVID-19 patients Phase III clinical failure; Astella ADC therapy approved clinical ... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original article) "Drug Research and Development" protection effect of 91.4% Russian new crown vaccine completed phase 3 clinical trial efficacy final analysis today, the Ministry of Health of the Russian Federation Gamaleya National Epidemiology and Microbiology Research Center and the Russian Direct Investment Fund announced that the new coronavirus vector platform developed by Sputnik V, in randomized double-blind, placebo-controlled phase 3 clinical trial final control point data analysis, reached more than 90% prevention effectiveness.
and Platinum Pharma jointly announced the launch of AbbVie's new Coronary Antibody Phase 1 clinical trial today, and Platinum Pharmaceuticals and the University of Utrecht jointly announced that they have authorized AbbVie's all-human source and antibody ABBV-47D11 for COVID-19 and related coronavirus prevention and treatment.
AbbVie will start the clinical research project in the United States and expand to Europe.
For the new coronavirus-induced CRS Eglin Pharmaceutical oral candidate drug Phase 1 clinical start today, Shenzhen Eglin Pharmaceutical announced that the company developed oral treatment drug for moderate/severe new coronary pneumonia - EG009 softgel clinical phase 1 trial was officially launched on December 10, 2020 U.S. Eastern Time, will be developed for the treatment of the new coronavirus-induced cytokine storm.
Novartic JAK inhibitor Jakavi treated hospitalized COVID-19 patients with Phase III clinical failure! On the 14th, Novartis announced that phase III clinical trials (RUXCOVID) for the treatment of new coronavirus pneumonia (COVID-19) hospitalized patients with oral JAK1/2 inhibitor Ruxolitinib (Jakafi/Jakavi) Joint Standard Care (SoC) had not reached the main endpoint.
PROTAC re-positive efficacy data Arvinas shares jumped 95% on the 14th, the development of PROTAC protein degradation agent leader Arvinas announced its product pipeline of another drug ARV-471 for breast cancer patients in phase I positive efficacy data, but also the latest release of ARV-110 clinical data for prostate cancer patients.
the news, Arvinas shares closed up 95 per cent with a market capitalisation of $2,367m.
Green leaf pharmaceutical antidepressant new drug completed China Phase III clinical main efficacy indicators observation 14, Green leaf pharmaceutical group announced that its independent research and development of new compounds and China's new class 1 drug anthochloric acid slow release tablet (LY03005) in China has completed a placebo efficacy and safety comparison of Phase III clinical trials of the group and follow-up.
all patients are now out of the group, in a blind state to complete the main efficacy indicator MADRS 10 score total score than the baseline change observation.
Q-K combination therapy NSCLC I/II clinical effect is planned for phase III clinical Q-K treatment program for the first, non-blind, multi-arm phase I/II clinical trial, mainly to assess the safety and toerability of Quavonlimab combination K drugs for first-line treatment of patients with late NSCLC, followed by ORR, PFS, total survival (OS) and DOR indicators.
"Drug Approval" Aubudini listing application into the "in the approval" No cheng Jianhua will welcome the first innovative drug approved today, NMPA drug registration progress inquiry results show that Noshing Jianhua BTK inhibitor Aubudini's two listing application status has been updated to "in the approval."
, according to prior CDE priority review public information, the two listing applications for Obudini corresponding to the adaptive disorders are: chronic lymphocytic leukemia / small lymphocyte lymphoma and sleeve lymphoma patients.
twice a year! Roche multiple sclerosis drug Ocrevus was approved by the FDA on the 14th, Roche's gene Genentech announced that the U.S. FDA has approved a two-hour shorter infusion time of Ocrevus® (ocrelizumab) for patients with relapsed or primary multiple sclerosis (MS) who have never experienced any severe infusion reaction (IRs) before.
a new "first-in-class" drug! Astellas ADC therapy has been approved for clinical CDE in China, the latest public announcement, Astella injection enfortumab vedotin obtained two clinical trials implied permission to develop for local late stage or metastatic urethra skin cancer.
public information shows that this is a target Nectin-4 "first-in-class" ADC, the FDA awarded breakthrough therapy recognition and priority review qualification, and was approved for listing in the United States at the end of 2019.
30 million Hetti insulin champion products! Gan Li took the country's first Gan Li Pharmaceuticals today announced that the company received the Approval of the State Drug Administration issued the Mendong insulin 30 injection "Drug Registration Approval", Gan Li Pharmaceuticals in May this year won the first mendong insulin injection in the country, this time won the mendong insulin 30 injection the first in the country.
Enhua to win the first review! 2 billion anaesthetic original research defeat recently, NMPA official website released the latest approved product information, Enhua Pharmaceuticals'acid suffentini injection 3 types of imitation market application was approved and treated as reviewed, earlier only IDT approved imports and Yichang People's Fu Pharmaceuticals obtained domestic approval, the product for the annual sales of more than 2 billion heavy anaesthetic injections.
the cover article of the Latest Research! The latest findings of Xinda Bio's new TIM-3 monoantitonic resistance were published recently, and the cover article of Antibody Therapeutics published the latest findings of Xinda Bio-Tim-3 monoantigen IBI104.
article shows that IBI104 has the potential to completely block THEM-3 signal, IBI104 and PD-1 antibody drugs combined to show better than PD-1 antibody single drug efficacy, can provide a new method for tumor immunotherapy.
。